We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Handheld Saliva Test Accurately Detects Breast Cancer

By LabMedica International staff writers
Posted on 05 Aug 2025

Breast cancer affects approximately one in eight women, and early detection through screening significantly increases the chances of successful treatment. More...

While mammograms and MRIs are effective, many women face barriers such as fear of discomfort, high costs, and time constraints. These challenges can lead to delays or avoidance of essential screening, especially in underserved and rural communities. Now, a new portable, easy-to-use diagnostic device offers a noninvasive solution that can detect breast cancer from a saliva sample, minimizing false negatives and even distinguishing between various stages of the disease.

Researchers at the University of Florida (Gainesville, FL, USA) and National Yang Ming Chiao Tung University (Hsinchu, Taiwan), along with collaborators, have developed a handheld biosensor aimed at improving breast cancer detection and monitoring. The device consists of a reusable mini printed circuit board paired with commercially available glucose test strips and a multi-channel test strip that can analyze several biomarkers at once, reducing costs. The test is simple: after saliva is collected in a small cup, the strip is dipped into the sample for three seconds, inserted into the sensor, and the results appear on a display and are sent to a phone or tablet via Bluetooth. This streamlined design improves accessibility and affordability, enabling near-real-time breast cancer screening even in low-resource settings.

During testing with 29 saliva samples, the device correctly identified breast cancer in all patients who had it (100% sensitivity) and identified healthy individuals 86% of the time, minimizing false negatives. The findings, published in Biosensors, show that it could also differentiate between healthy individuals, those with carcinoma in situ, and those with invasive breast cancer. The team envisions the biosensor becoming a triage tool to guide decisions about further screening through mammograms or MRIs. Future plans include testing additional saliva biomarkers to fine-tune the device’s accuracy and expanding its potential to detect other diseases.

“It’s very exciting because this device could improve access to breast cancer screening and significantly reduce health care costs,” said Coy Heldermon, M.D., Ph.D., breast oncologist at UF Health and co-author of the study. “If all holds true, it would be a game-changer.”

Related Links:
University of Florida
National Yang Ming Chiao Tung University


New
Gold Member
Automatic Hematology Analyzer
DH-800 Series
Collection and Transport System
PurSafe Plus®
Urine Chemistry Control
Dropper Urine Chemistry Control
6 Part Hematology Analyzer with RET + IPF
Mispa HX 88
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: New evidence shows viscoelastic testing can improve assessment of blood clotting during postpartum hemorrhage (Photo courtesy of 123RF)

Viscoelastic Testing Could Improve Treatment of Maternal Hemorrhage

Postpartum hemorrhage, severe bleeding after childbirth, remains one of the leading causes of maternal mortality worldwide, yet many of these deaths are preventable. Standard care can be hindered by delays... Read more

Industry

view channel
Image: The partnership between OGT and QIAGEN unlocks a complete sample to report workflow for SureSeq NGS panels (Photo courtesy of OGT)

Qiagen and Oxford Gene Technology Partner on Sequencing Panel Interpretation

In clinical research, next-generation sequencing (NGS) panels provide essential insights for genetic analysis, but many laboratories face challenges in transforming raw sequencing data into clinically... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.